Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells

ZHEN YU1, LIN LIU1, QIANG SHU2, DONG LI2 and RAN WANG3

1Department of Pediatrics, Qilu Hospital, Shandong University, Jinan, Shandong 250012; 2Department of Immunology, Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong 518057; 3Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China

Received July 25, 2018; Accepted April 15, 2019

DOI: 10.3892/ol.2019.10767

Abstract. Leukemia stem cells (LSCs) are responsible for therapeutic failure and relapse of acute lymphoblastic leukemia. As a result of the interplay between LSCs and bone marrow mesenchymal stem cells (BM-MSCs), cancer cells may escape from chemotherapy and immune surveillance, thereby promoting leukemia progress and relapse. The present study identified that the crosstalk between LSCs and BM‑MSCs may contribute to changes of immune phenotypes and expression of hematopoietic factors in BM-MSCs. Furthermore, Illumina Genome Analyzer /Hiseq 2000 identified 7 differentially expressed genes between BM-MSC-LSC and BM-MSCs. The Illumina sequencing results were further validated by reverse transcription-quantitative polymerase chain reaction. Following LSC simulation, 2 genes were significantly upregulated, whereas the remaining 2 genes were significantly downregulated in MSCs. The most remarkable changes were identified in the expression levels of lumican (LUM) gene. These results were confirmed by western blot analysis. In addition, decreased LUM expression led to decreased apoptosis, and promoted chemoresistance to VP-16 in Nalm-6 cells. These results suggest that downregulation of LUM expression in BM-MSCs contribute to the anti-apoptotic properties and resistance to chemotherapy in LSCs.

Introduction

Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood cancer. Treatment of pediatric ALL is effective as chemotherapy results in the treatment of >80-85% ALL pediatric patients (1-4). Nevertheless, a total of 20-30% of pediatric patients will ultimately relapse and succumb to the disease. Residual leukemia stem cells (LSCs) are chemoresistant cells, which are able to escape from immune surveillance. These abilities may be responsible for therapeutic failure and relapse of ALL (5). LSCs may be regulated by bone marrow mesenchymal stem cells (BM-MSCs), which in turn may improve the survival of LSCs by providing the necessary cytokines and cell contact-mediated signals. For instance, previous experimental data indicated that LSCs accumulated in close association with BM-MSCs, which might regulate their proliferation, differentiation and chemoresistance (6). Therefore, it is critical to further understand the association between LSCs and BM-MSCs.

The finding of ‘donor cell leukemia’ (DCL) confirms the important role of the hematopoietic microenvironment in hematopoietic stem cell regulation (7). BM-MSCs, an important component of the BM environment, act as hematopoietic regulators through producing cytokines, chemokines, adhesion molecules and extracellular matrix molecules. BM-MSCs are also considered as a major source for the secretion of the homeostatic chemokine, stromal cell-derived factor 1 (SDF-1) also known as C-X-C motif chemokine 12 (CXCL12), which serves a critical role as a homing signal of circulating HSCs, and in the regulation of immune responses (8). However, whether LSC may influence the hematopoietic microenvironment remains poorly studied. In the present study, CD34+ cells were isolated from Nalm-6 cells and used as LSCs in further experiments. CD34 protein is used as a surface marker to identify hematopoietic stem cells and LSCs (9). Subsequently, the effect of LSCs stimulation on immunophenotype and expression of hematopoietic genes in BM-MSCs was evaluated. A gene sequencing method was used to detect the changes of gene expression levels in MSCs induced by LSCs.

Materials and methods

Cell cultures. The human pre-B cell leukemia Nalm-6 cell line, was supplied by The American Type Culture Collection

Correspondence to: Professor Ran Wang, Department of Hematology, Qilu Hospital, Shandong University, 107 Wenhuaixilu Road, Jinan, Shandong 250012, P.R. China
E-mail: wangran_78@126.com

Professor Dong Li, Department of Immunology, Shenzhen Research Institute of Shandong University, 19 Gaoxinansidao Road, Nanshan, Shenzhen, Guangdong 518057, P.R. China
E‑mail: lidong73@sdu.edu.cn; lidong_sdu@163.com

Key words: leukemia stem cell, acute lymphoblastic leukemia, bone marrow mesenchymal stem cells, lumican, Illumina sequencing
and was cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin G and 100 mg/ml streptomycin at 37°C in a humidified 5% CO₂ incubator. Human BM-MSCs were purchased from ScienCell Research Laboratories, Inc. and cultured in low-glucose DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10%, 100 U/ml penicillin G and 100 mg/ml streptomycin at 37°C in a humidified 5% CO₂ incubator.

**CD34 positive B-lineage LSCs enrichment.** CD34 protein was used as a surface marker to identify LSCs in Nalm-6. CD34 positive cells were isolated from Nalm-6 cells through immunomagnetic bead-positive selection using a CD34⁺ MicroBead kit (Miltenyi Biotech, Inc.) according to the manufacturer’s instructions to a purity of 90-96% as determined by flow cytometry. Purity was confirmed by flow cytometry with anti-CD34 (dilution 1:10, phycoerythrin-labeled; cat. No. 550761; BD Pharmingen) and was >95% in all experiments.

**Co-culture of LSCs with BM-MSCs.** To study the effect of Nalm-6 cell stimulation on BM-MSCs, LSCs were co-cultured with an adherent monolayer of BM-MSCs at a 10:1 ratio for 24-72 h. To perform co-culture experiments, continuous culture of BM-MSCs was maintained and plated at a concentration of 1x10⁵ cells/well, 24 h before adding LSC cells at a concentration of 1x10⁶ cells/well. Although LSCs are constantly interacting with stroma, these lymphocytes do not adhere to plastic or to BM-MSCs. Co-cultured LSCs were carefully separated from BM-MSCs monolayer by pipetting with ice-cold PBS, leaving the adherent BM-MSCs layer undisturbed. Subsequently, BM-MSCs were trypsinized and used for transcriptome sequencing, and pharmacological and biochemical end points.

**Detection of BM-MSCs immune-phenotype using flow cytometry.** BM-MSCs and BM-MSCsLSC were collected and treated with 0.25% trypsin. The cells were individually stained with fluorescein isothiocyanate or phycoerythrin-conjugated anti-marker monoclonal antibodies in 100 µl PBS for 15 min at room temperature or for 30 min at 4°C, as recommended by the manufacturer. The antibodies used were specific for the human antigens, CD29 (cat. No. 557332), CD31 (cat. No. 560983), CD34 (Cat. 550761), CD44 (Cat. 562818), CD45 (cat. No. 560975), CD73 (cat. No. 562430), CD90 (cat. No. 561970), and CD105 (cat. No. 560839; all at 1:10; all from BD Pharmingen). Cells were analyzed on a flow cytometry system (Guava easyCyte8HT; EMD Millipore) with the Guava Incyte software (version 2.8; EMD Millipore). Positive cells were counted and the signals for the corresponding immunoglobulin isotypes were compared.

**Transcriptome sample preparation and sequencing.** Total RNA was isolated from BM-MSCs using TRIzol® (Ambion, RNA Life Technologies) according to the manufacturer's procedures. RNA integrity was assessed using the RNA6000 Pico assay kit on the Bioanalyzer 2100 system (Agilent Technologies, Inc.). Sequencing libraries were generated using the Illumina TruSeq™ RNA sample preparation kit (Illumina, Inc.) following the manufacturer's recommendations and 4 index codes were added to attribute sequences to each sample. The clustering of the index-coded samples was performed on a cBot Cluster Generation system using TruSeq PE Cluster kit v3-cBot-HS (Illumina, Inc.) according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina Hiseq2000 platform and 100 bp paired-end reads were generated.

**Sequencing data analysis.** Quality control: Raw data (raw reads) in the fastq format were firstly processed through in-house perl script. Differential expression analysis of two conditions/groups (two biological replicates per condition) was performed using the DESeq R package (version 1.10.1) (10). DESeq provides statistical routines for determining differential expression in digital gene expression data using a model based on the negative binomial distribution. The resulting P-values were adjusted using the Benjamini and Hochberg approach for controlling the false discovery rate. Genes with an adjusted P-value <0.05 found by DESeq were assigned as differentially expressed. Differential expression analysis of two conditions was performed using the DESeq R package (version 1.12.0) (11). The P-values were adjusted using the Benjamini and Hochberg method. Corrected P-value of <0.005 and log 2 (fold-change) of 1 were set as the threshold for significantly differential expression.

**RNA isolation and reverse-transcription quantitative PCR (RT-qPCR).** RT-qPCR analysis was performed to confirm the expression profiles obtained from RNA sequencing. Total cellular RNA was isolated from BM-MSCs and BM-MSCsLSC using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) as per the manufacturer's protocol. Nucleotide sequences of primers used for PCR analysis are listed in Table I. For each set of primers, a gradient PCR was performed to determine the optimal annealing temperature. Optimal annealing temperature was determined using 1°C increments in 12 different wells. The thermocycling conditions were as follows: 10 min at 95°C for initial denaturation; and 35 cycles of 95°C for 15 sec, 60°C for 2 min, and 72°C for 30 sec. cDNA purified from BM-MSCs were used as template. A high annealing temperature was used to prevent or limit non-specific binding. qPCR was performed using an ABI 7500 PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) and SYBR-Green 1 dye (Toyobo Life Science). Serial dilutions of cDNA samples (between 1:10 and 1:1,000) were analyzed to determine efficiency and dynamic range of the PCR, using GAPDH as endogenous control. Each gene expression relative to β-actin was determined using the 2^-ΔΔCT method (12), where ΔCTq=target gene-ΔCTβ-actin. Total RNA (0.2 µg) was reverse transcribed in a 20 µl reaction mixture containing the following components: 1X RT buffer, deoxynucleotide triphosphate mix (5 mM each), RNase inhibitor (10 U/µl RNaseOut; Invitrogen; Thermo Fisher Scientific, Inc.), and 4 units Omniscript reverse transcriptase (Qiagen GmbH). Each sample was reversed transcribed for 30 min at 38°C. By optimizing the annealing temperature, the thermocycling conditions of PCR were as follows: 10 min at 95°C for initial denaturation; and 40 cycles of 95°C for 15 sec and 60°C for 2 min. Successful amplification was determined by the presence of a single dissociation peak on the thermal melting curve. Data were analyzed with the sequence...
detection software (version 1.4; Applied Biosystems; Thermo Fisher Scientific, Inc.). Results are expressed as the normalized fold expression for each gene. Reported data are representative of at least three independent experiments.

**Recombinant plasmid construction and transfection.** To study the effects of the overexpression and downregulation of the *lumican* (*LUM*) gene, pcDNA3.1-LUM and 3 small interfering RNA (siRNA) sequences targeting *LUM* were designed and synthesized (Shanghai GenePharma Co., Ltd.). The nucleotide sequences of the 3 groups were as follows: Group 329 (the number represents the starting position of the different siRNA cleavages on the mRNA sequence), 5'-CTG CTT TAA GAA TTA ACG AAA GC-3', group 437, 5'-CAG TGG CCA GTA GAG ACT TGT TGC-3', and group 540, 5'-GTC CCA GAG GAG CGT GAT TGA ACG AAG TGA ACG-3'.

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5'-3')</th>
<th>Product size, bp</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH‑F</td>
<td>GACAGTCAGCCGCATCTTCT</td>
<td>104</td>
</tr>
<tr>
<td>GAPDH‑R</td>
<td>GCGCCCAATACGACCAATC</td>
<td>89</td>
</tr>
<tr>
<td>IL‑1α‑F</td>
<td>GACGCCCTCAATCAAAGTATAATT</td>
<td>80</td>
</tr>
<tr>
<td>IL‑1α‑R</td>
<td>TCAAAATTTCAGTTGCGCATCCAGAT</td>
<td>85</td>
</tr>
<tr>
<td>IL‑1β‑F</td>
<td>GCGGCATCCAGCTACGAAT</td>
<td>80</td>
</tr>
<tr>
<td>IL‑1β‑R</td>
<td>GTCCATGGCCAAACAACATG</td>
<td>86</td>
</tr>
<tr>
<td>IL‑10‑F</td>
<td>GCCTTGTGCTGAGATGATCCAGTT</td>
<td>85</td>
</tr>
<tr>
<td>IL‑10‑R</td>
<td>TCACATGGCCCTTGTGCTT</td>
<td>104</td>
</tr>
<tr>
<td>IL‑6‑F</td>
<td>GCAAAGAGGCCACGTGCCAGAA</td>
<td>93</td>
</tr>
<tr>
<td>IL‑6‑R</td>
<td>GCGAAGTCTCCTCATTTGAATCC</td>
<td>86</td>
</tr>
<tr>
<td>IL‑7‑F</td>
<td>AACAGCTCGAGATGACACCC</td>
<td>116</td>
</tr>
<tr>
<td>IL‑7‑R</td>
<td>CTACCCGCCCATATGCATCT</td>
<td>104</td>
</tr>
<tr>
<td>IL‑11‑F</td>
<td>ACATGAACGTGTTTGCGCG</td>
<td>128</td>
</tr>
<tr>
<td>IL‑11‑R</td>
<td>GCTGTGGGGAAATCGAGGG</td>
<td>139</td>
</tr>
<tr>
<td>SCF‑F</td>
<td>TCGATGACCTTGTGGAGTGC</td>
<td>84</td>
</tr>
<tr>
<td>SCF‑R</td>
<td>TAAAAGGGCTGTTGCTGGG</td>
<td>134</td>
</tr>
<tr>
<td>IL‑3‑F</td>
<td>GACTCCAAAGCTCCCATGACC</td>
<td>86</td>
</tr>
<tr>
<td>IL‑3‑R</td>
<td>GTCCAGCAAAAGCAAGGTCG</td>
<td>116</td>
</tr>
<tr>
<td>G‑CSF‑F</td>
<td>TTGACTCCCGAAACATCACC</td>
<td>128</td>
</tr>
<tr>
<td>G‑CSF‑R</td>
<td>CAAGGCAATGTCCAGGCAC</td>
<td>139</td>
</tr>
<tr>
<td>SDF‑1‑F</td>
<td>AGATTGTAACCGCGGTCGAAG</td>
<td>134</td>
</tr>
<tr>
<td>SDF‑1‑R</td>
<td>GTGGGTCTAGCAGGAAAGTCC</td>
<td>115</td>
</tr>
<tr>
<td>LIF‑F</td>
<td>TGGGCCAATTTGTTGAGAGG</td>
<td>139</td>
</tr>
<tr>
<td>LIF‑R</td>
<td>TATCTGCGAGGAAACATGCG</td>
<td>139</td>
</tr>
<tr>
<td>TRIB3‑F</td>
<td>GAGACTCCGCACGCGAAATG</td>
<td>139</td>
</tr>
<tr>
<td>TRIB3‑R</td>
<td>CTCAGAGGCGCTCCAGGCA</td>
<td>134</td>
</tr>
<tr>
<td>SLC7A5‑F</td>
<td>TCATCATCAGGCGATTCCATG</td>
<td>134</td>
</tr>
<tr>
<td>SLC7A5‑R</td>
<td>GAGCAGCAACCGAGCA</td>
<td>132</td>
</tr>
<tr>
<td>WSB1‑F</td>
<td>GTCAACGGAGAAGAGATCTCGAG</td>
<td>152</td>
</tr>
<tr>
<td>WSB1‑R</td>
<td>ACTGTGCCATGTCTCTTGTA</td>
<td>152</td>
</tr>
<tr>
<td>NKTR‑F</td>
<td>GGAGCCAGGATGATGACACGC</td>
<td>139</td>
</tr>
<tr>
<td>NKTR‑R</td>
<td>GTGTAGACCTTGATCGACTG</td>
<td>115</td>
</tr>
<tr>
<td>LUM‑F</td>
<td>CCGTCTCAGCAGGTTCACAG</td>
<td>115</td>
</tr>
<tr>
<td>LUM‑R</td>
<td>TGGGAAATGTTGGAATCCTTACTG</td>
<td>150</td>
</tr>
<tr>
<td>OGT‑F</td>
<td>GCTGTCGCTCTTGTACTCT</td>
<td>150</td>
</tr>
<tr>
<td>OGT‑R</td>
<td>ACGTTCGTTGTTTCTGTGAC</td>
<td>135</td>
</tr>
<tr>
<td>LENG8‑F</td>
<td>CGAAGGATCCTGTGAGCATG</td>
<td>135</td>
</tr>
<tr>
<td>LENG8‑R</td>
<td>CAGCCACCATGCTGTACTGA</td>
<td>135</td>
</tr>
</tbody>
</table>

F, forward; R, reverse; IL, interleukin; SCF, SKP1-CUL1-F protein; G-CSF, granulocyte-colony stimulating factor; LIF, leukemia inhibitory factor; SDF-1, stromal cell-derived factor 1; SLC7A5, solute carrier family 7 member 5; TRIB3, tribbles pseudokinase 3; WSB1, WD repeat and SOCS box containing 1; NKTR, natural killer cell triggering receptor; LUM, lumican; OGT, O-linked N-acetylglucosamine (GlcNAc) transferase; LENG8, leukocyte receptor cluster member 8.
CTATGATTGAT-3', and group 467, 5'-CTATCAATTTA TGGGCAATCATCA-3'. For construction of the expression plasmid, the Lumican inserts were isolated by PCR amplification (Novoprotein) and digested with the restriction endonucleases EcoRI and BglII (MBI Fermentas; Thermo Fisher Scientific, Inc.), and linked into the pcDNA3.1 expression plasmids (Bio-Asia Company) with T4 DNA ligase (TransGen Biotech, Co., Ltd.). The ligation products were transformed into competent *Escherichia coli* DH5α (TransGen Biotech, Co., Ltd.) and then selected using the kanamycin resistance method. Recombinant plasmids were sequenced (ABI Prism 3100 DNA Sequencer; Applied Biosystems; Thermo Fisher Scientific, Inc.) and confirmed to contain the entire coding sequence of LUM.

The cells were seeded into 6-well plates and cultured to 70% confluence for siRNA transfection (25 nM) and plasmid transfection, respectively, for 24 h. Transfection was performed using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol, and the culture medium was replaced after 6 h of incubation. After 72 h of transfection, the cells were counted and subjected to cell cycling and apoptosis assay, and western blot analysis. The untransfected cells were considered to be blank control, and the cells transfected with scrambled siRNA (5'-CATCATAGTCAGTACTGATGT-3') were considered as the negative controls (NCs) for the downregulation experiments. The cells transfected with Lipofectamine only (Mock) or pcDNA3.1 (empty vector) were considered as the control for the upregulation experiments. Cells transfected with the BLOCK-iT™ Alexa Fluor® Red Fluorescent Control (Invitrogen; Thermo Fisher Scientific, Inc.) were used to determine the transfection efficiency of siRNA.

**Cell cycling analysis of BM-MSCs-LUM+/− to Nalm-6 cells.** The experiment was divided into four groups: Normal nalm-6 cells, nalm-6+normal BM-MSCs, nalm-6+BM-MSCs-cDNA3.1-LUM, and nalm-6+BM-MSCs-LUM-437 groups. After co-culture for 24 h, a total of 1×10⁵ nalm-6 cells collected from each group were washed three times with PBS and resuspended in 50 µl PBS. Resuspended cells were added, dropwise, into a tube containing 1 ml ice cold 70% ethanol while vortexing at medium speed. The tubes were frozen at -20°C for 3 h prior to staining. Afterwards, the cells were washed and treated with propidium iodide (PI) staining kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol. After 30 min of incubation at room temperature in the dark, cell suspension samples were subjected to cell cycling and apoptosis assay, and western blot analysis. The untransfected cells were considered to be blank control, and the cells transfected with scrambled siRNA (5'-CATCATAGTCAGTACTGATGT-3') were considered as the negative controls (NCs) for the downregulation experiments. The cells transfected with Lipofectamine only (Mock) or pcDNA3.1 (empty vector) were considered as the control for the upregulation experiments. Cells transfected with the BLOCK-iT™ Alexa Fluor® Red Fluorescent Control (Invitrogen; Thermo Fisher Scientific, Inc.) were used to determine the transfection efficiency of siRNA.

**Cytotoxicity assay of VP-16.** The effect of BM-MSCs-LUM+/− on the sensitivity of the Nalm-6 cell line to VP-16 (Sigma-Aldrich; Merck KGaA) was evaluated using Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) assay. The experiment was divided into five groups: VP-16+Nalm-6 cells (control group), VP-16 + Nalm-6 cells + normal BM-MSCs (group 1), VP-16 + Nalm-6 + BM-MSCs-LUM-329 (group 2), VP-16 + Nalm-6 + BM-MSCs-LUM-437 (group 3), and VP-16 + Nalm-6 + BM-MSCs-cDNA3.1-LUM (group 4). The cells treated with only 0.9% normal saline were used as VP-16 blank controls. In brief, the Nalm-6 cells were cultivated at a density of 2×10⁴ cells/well in 96-well culture plates, groups 2, 3, 4, and 5 were pre-layered with BM-MSCs as the feeder cells. Nalm-6 cells were treated with various concentrations of VP-16 (0, 0.05, 0.1 and 0.5 µg/ml). After 48 h of culture, the cytotoxicity of the treatments was determined using CCK-8 dye according to the manufacturer's instructions. The generated formazan was determined using a model 450 microplate reader (Bio-Rad Laboratories, Inc.) at an optical density of 570 nm to determine cell viability. Survival rate (SR) was calculated using the following equation: SR (%)=(A Test/A Control)x100%.

**Statistical analysis.** All data are presented as mean ± SEM from three separate experiments. Data were analyzed using the Student's t-test for comparison between two groups or Tukey's post-hoc tests for comparison among multiple groups as appropriate. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS (version 17.0; SPSS, Inc.).
Results

LSCs regulate the phenotype and the expression of hematopoietic factors in BM-MSCs. Following LSCs simulation for 24-72 h, the expression levels of hematopoietic factors proteins on BM-MSCs were evaluated by flow cytometry. The results showed that there were no significant differences in the expression of surface markers observed except for CD44 and CD105, CD44 was significantly upregulated and CD105 was downregulated (Table II).

mRNA levels of hematopoietic factors were evaluated in BM-MSCs following co-culture with LSCs for 24-72 h. In contrast to SDF-1 and interleukin (IL)-6, which had reduced levels, the majority of hematopoietic factors, including IL-3, IL-7, IL-10 and G-CSF, were upregulated in BM-MSCs compared with BM-MSCs group (P<0.01). The results of SCF and LIF were also higher in the BM-MSCs group (P<0.05). Collectively, these results suggest that the crosstalk of LSCs and BM-MSCs result in changes in the expression of hematopoietic factors in the BM microenvironment.

Differentially expressed genes in BM-MSCs. Illumina Genome Analyzer/Hiseq 2000 was performed to identify differentially expressed genes between BM-MSCs and BM-MSCs. The data revealed significant upregulation of 2 genes [solute carrier family 7 member 5 (SLC7A5) and tribbles pseudokinase 3 (TRIB3)] and significant downregulation of 5 genes [WD repeat and SOCS box containing 1 (WSB1), natural killer cell triggering receptor (NKTR), lumican (LUM), O-linked N-acetylglucosamine (GlcNAc) transferase (OGT), leukocyte receptor cluster member 8 (LENG8)] in BM-MSCs after LSC simulation for 24-72 h (Table III). RT-qPCR analysis was performed to confirm the expression profiles obtained by RNA sequencing. P<0.05 was considered to indicate a statistically significant difference. As revealed in Table III, TRIB3 and NKTR were upregulated, while SLC7A5, LUM and LENG8 were downregulated in BM-MSCs compared with BM-MSCs group.
The expression of TRIB3 in BM-MSCsLSC group were higher than that in BM-MSCs group (P<0.05). The expression levels of SLC7A5 and LUM in BM-MSCsLSC group were significantly lower than those in BM-MSCs group (P<0.01). Notably, the results of PCR revealed a decrease in SLC7A5, which was inconsistent with the results from RNA sequencing, therefore
SLC7A5 was not chosen as the target for further experiments. The reduced expression levels of LUM were consistent with the results from the Illumina sequencing data. Therefore, LUM was selected for further experiments.

Up or downregulation of LUM in BM-MSCs. Whether changes in LUM expression of BM-MSCs could serve a critical role in Nalm-6 cells was also evaluated. BM-MSCs were transfected with pcDNA3.1-LUM vector or siRNAs (siRNA329, siRNA437 and siRNA467). After colony selection for 2 weeks, expression of LUM in transfected BM-MSCs was confirmed by western blotting (Fig. 3). The results revealed that expression of LUM in LUM-transfected BM-MSCs (Lum) was >2-fold increase compared with that in mock and pcDNA3.1-transfected cells (P<0.01). By contrast, in siRNA329 and siRNA437-transfected BM-MSCs (siLUM), LUM mRNA transcripts were down-regulated, compared with untransfected BM-MSCs and scrambled siRNA-transfected BM-MSCs (Fig. 3). siRNA329 and siRNA437 were utilized further to inhibit the expression of LUM. Transfection efficiency was ~43%.

Effect of LUM downregulation on cell cycle distribution in Nalm-6 cells. Flow cytometry analysis revealed that the fraction of cells in G0/G1 phase increased, and the proportion of cells in G/M phase decreased in Nalm-6 + BM-MSCs group compared with Nalm-6 cells group. Compared with Nalm-6 cells group, there was a significant increase in the percentage of cells in G0/G1 phase in the Nalm-6+BM-MSCs-LUM-329 and Nalm-6+BM-MSCs-LUM-437 (P<0.05) and a significant decrease in the S phase (P<0.01) and G2/M phase (P<0.01, 0.05). However, increasing LUM expression (Nalm-6+BM-MSCs-cDNA3.1-LUM group) decreased the percentage of cells in G0/G1 and S phase (both P<0.05), but increased the percentage of cells in G2/M phase compared with Nalm-6+BM-MSCs group (P<0.01; Fig. 4).

Downregulation of LUM decreases apoptosis in Nalm-6 cells. To determine whether LUM expression affects the apoptosis of Nalm-6 cells, the cells were stained with Annexin V/PI after 24 h of co-culture. The percentage of cells in both early and late apoptosis were significantly decreased in the LUM-silenced group (Nalm-6+BM-MSCs-LUM-329 and Nalm-6+BM-MSCs-LUM-437 group) compared with the Nalm-6+BM-MSCs group (P<0.01; Fig. 5). Compared with Nalm-6+BM-MSCs group, the numbers of apoptotic cells remained unchanged in Nalm-6+BM-MSCs-cDNA3.1-LUM group.

Downregulation of LUM decreases the sensitivity of Nalm-6 cells to VP-16. Whether changes in LUM expression may affect the sensitivity of Nalm-6 cells to VP-16, a chemotherapy medication used for the treatment of various types of cancer was also assessed. LUM-expressing BM-MSCs and LUM-silencing BM-MSCs were treated with VP-16 and CCK-8 was used to assess cytotoxicity. Treatment with VP-16 displayed cytotoxicity in BM-MSCs in a dose-dependent manner (Fig. 6A). Coculture with BM-MSCs (Nalm-6+VP16+normal BM-MSCs group) increased the cell viability compared with the Nalm-6+VP16 group (P<0.05). Silencing of LUM (Nalm-6+BM-MSCs-LUM-329 and Nalm-6+BM-MSCs-LUM-437 group) also increased the cell viability compared with the Nalm-6+VP16 group (P<0.01). In contrast, Nalm-6+BM-MSCs-cDNA3.1-LUM group reduced the cell viability compared with Nalm-6+VP16 + normal BM-MSCs group, but this effect was not significant (P>0.05; Fig. 6B).
In the present study, it was demonstrated that Nalm-6 cell-derived CD34+ LSCs significantly upregulated CD44 expression and altered the expression of different hematopoietic factors in BM-MSCs following co-culture. LUM was downregulated in BM-MSCs as assessed by Illumina Genome Analyzer/Hiseq 2000 and RT-qPCR. In addition, a recombinant eukaryotic expression plasmid or siRNA were used to overexpress or inhibit the expression of the lumican gene. The results suggest that downregulated LUM expression in BM-MSCs contribute to the anti-apoptotic properties and resistance to chemotherapy in Nalm-6 cells.

CD44 is a widely distributed cell-surface glycoprotein involved in lymphocyte adhesion to the vascular endothelium and extracellular matrix proteins (13). As a major receptor of hyaluronic acid (HA) (14), CD44 participates in diverse cellular processes during tumorigenesis, including cell transformation, proliferation, metastasis and apoptosis (5,15,16). CD44 is required for LSCs to efficiently lodge in and home to...
the BM niche in AML, and anti-CD44 antibodies may modify the fate of the LSCs via inducing differentiation (6). In addition, CD44-HA crosstalk mediates LSC apoptosis resistance by initiating signal transduction and cooperating with multi-drug resistance genes (17). The results of the present study demonstrated that CD44 expression of BM-MSCs was significantly increased after LSC simulation. Therefore, LSCs may induce MSCs to express increased levels of CD44. This results in LSCs staying closer to MSCs for longer periods of time, thus additional shelter from stromal cells. On the other hand, it can create a microenvironment promoting the proliferation of LSCs and prevent the damage caused by chemotherapeutic drugs, thus contributing to relapse of ALL.

An intricate network of cytokine and cytokine receptors is involved in the crosstalk between LSCs and BM-MSCs, which may deregulate normal hematopoiesis and offer a selective growth advantage to LSCs in leukemia. SDF-1/CXCL12, is critical for the homing of hematopoietic cells to the BM through its receptor, CXCR4 (18). Specific antagonists, which may block the interaction between CXCL12 and CXCR4, may disrupt the adhesion of malignant cells to the BM microenvironment and adipose tissue, rendering them more susceptible to chemotherapy (19). Due to the effects of SDF-1 on the pathophysiological procedure of leukemia, it was hypothesized that SDF-1 mRNA may be upregulated in BM-MSCs following co-culture with LSCs. Unexpectedly, it was found that SDF-1 mRNA was downregulated in BM-MSCs after LSC simulation. A previous study found that CXCL12 expression in BM-MSCs was reduced in BCR-ABL mice and CML patients (20). Maksym et al (21) reported that CXCL12/CXCR4 signaling was deregulated in patients with myelodysplastic syndromes and leukemia. Hematopoietic factors, including IL-10, IL-1α and IL-7 may promote progression of lymphoid malignancies and may be associated with clinical prognosis. Excessive production of SCF impairs normal BM niches and mediates the engraftment of CD34+ cells into the malignant niche. The SCF/c-kit-R pathway may be utilized as a therapeutic target for leukemia (22). These findings are consistent with the results of the present study. In accordance with previous studies (23-28), the results of the present study demonstrated reduced SDF-1 and IL-6 levels, and increased IL-10, G-CSF, IL-3, IL-7, SCF, IL-11, IL-1α, IL-1β and LIF levels after LSC-BM-MSCs co-culture for 24-72 h.

LUM is a member of the small leucine-rich proteoglycan family (29) and its overexpression has been reported in melanoma (30), breast (31), colorectal (32), uterine (33) and pancreatic cancer (34). In melanoma, decreased LUM expression correlates with increased tumor growth and progression (35,36), and increased LUM expression impedes tumor cell migration and invasion by directly interacting with the α2β1 integrin (37) and decreasing phosphorylated focal adhesion kinase phosphorylation (38). A previous study unambiguously linked LUM with pancreatic carcinoma cell metabolism and identified the LUM/epidermal growth factor receptor (EGFR)/Akt/hypoxia-inducible factor-1 α (HIF-1α) signaling pathway as a mechanism by which LUM may inhibit pancreatic cancer cell survival and proliferation (39). LUM enhances the internalization of EGFR from the cell membrane into the cytoplasm, resulting in autophosphorylation and subsequent internalization (40). The PI3K/Akt-mediated signaling pathway is a major downstream pathway of EGFR (41). LUM downregulates HIF-1α expression and activity through the EGFR/Akt signaling pathway. LUM may decrease glucose consumption, lactate production and intracellular ATP level and induce apoptosis through downregulation of HIF-1α (25). Using the Illumina Genome Analyzer/Hiseq 2000, it was identified that the expression of LUM was decreased in BM-MSCs (LSC). Additionally; decreased LUM expression led to decreased apoptosis and promoted chemoresistance to VP-16 in Nalm-6 cells, indicating that LSCs can alter the expression of key genes of BM-MSCs to promote leukemia survival. Decreased expression of LUM may also promote angiogenesis by interfering with α2β1 integrin and downregulating matrix metalloproteinase-14 expression (42). It is worth noting that only depletion for LUM in BM-MSCs significantly affected the cell cycle, apoptosis and drug resistance to Nalm-6, while overexpression of LUM did not show a significant effect compared with the blank control group. This may be due to the fact that the corresponding receptors on LSC have not increased accordingly.

In summary, the present study revealed that ALL cells may generate an abnormal inhibitory microenvironment for normal hematopoietic cells. Downregulation of LUM in BM-MSCs decreased apoptosis in Nalm-6 cells and the sensitivity of Nalm-6 cells to VP-16. However, the mechanism by which LUM interacts with other factors during the occurrence and development of leukemia remains unclear. These potential interactions should be further investigated in future studies.

Acknowledgements
Not applicable.

Funding
The present study was funded by Natural Science Foundation of China (grant no. 81473484), The Shenzhen Science and Technology Research and Development Fund (grant no. JCYJ20160331173652555) and The Shandong Province Major Scientific Research Projects (grant no. 2017GSF218015).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
RW and DL conceptualized the study and designed the protocol. DL performed the literature search. LL and QS performed the experiments. All authors analyzed and interpreted the data. ZY performed the experiments and drafted the manuscript. All authors approved the final version of the manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.
Competing interests

The authors declare that they have no competing interests.

References


